why choose us

First received: December 09, 2024

Clinical Trial: A Trial Comparing Pharmacokinetics, Safety and Tolerability of Two Subcutaneous Concentrations of Dapiglutide

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Overweight and Obesity

Study Type: INTERVENTIONAL


Official Title: An Open-label, Randomized, Parallel-group, Single-center Trial to Compare Pharmacokinetics of Dapiglutide After a Single Subcutaneous Dose of the Drug Product Concentrations 10 mg/mL or 25 mg

Brief Summary: This is a phase 1, open-label, single-center, randomized, parallel-group trial designed to investigate the pharmacokinetic profiles, safety, and tolerability of a single dose administration of 7.5 mg dapiglutide administered s.c. with two drug product concentrations, 10 mg/mL and 25 mg/mL.The trial will be conducted in participants with a BMI ? 27.0 kg/m2.

Read more